Intraperitoneal bleomycin. Pharmacokinetics and results of a phase II trial.
Bleomycin was administered in a phase II trial to 10 patients with malignant ascites. Complete responses to intraperitoneal bleomycin were observed in 6/10 patients (60%). Pharmacokinetics of serum and intraperitoneal bleomycin showed peak levels at 15 minutes with a peritoneal fluid half-life of 4.2 +/- 0.1 hours and a serum half-life of 5.0 +/- 1.2 hours. There was a 400-fold difference in concentration when bleomycin was administered intra-abdominally. Toxicities with intraperitoneal bleomycin were minimal. This phase II trial confirms the efficacy of intraperitoneal bleomycin; further trials appear warranted.
J D
JD
Bitran
D000008:Abdominal Neoplasms / Q000097:blood / Q000188:drug therapy* / Q000556:secondary; D000230:Adenocarcinoma / Q000097:blood / Q000188:drug therapy* / Q000556:secondary; D000368:Aged; D001201:Ascites / Q000188:drug therapy* / Q000628:therapy; D001202:Ascitic Fluid / Q000378:metabolism; D001761:Bleomycin / Q000009:adverse effects / Q000378:metabolism / Q000627:therapeutic use*; D004322:Drainage; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D007700:Kinetics; D008297:Male; D008875:Middle Aged; D010530:Peritoneal Dialysis
D001761:Bleomycin